Brokers Offer Predictions for Disc Medicine FY2026 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Wedbush upped their FY2026 earnings per share estimates for shares of Disc Medicine in a research report issued to clients and investors on Tuesday, January 21st. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($3.96) for the year, up from their previous estimate of ($4.19). Wedbush currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s FY2027 earnings at $2.64 EPS.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15.

Several other equities analysts also recently issued reports on IRON. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Scotiabank lifted their price target on Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Tuesday, October 15th. Stifel Nicolaus increased their price target on shares of Disc Medicine from $79.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Finally, Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a research note on Tuesday, November 5th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Disc Medicine has an average rating of “Buy” and an average price target of $88.50.

Disc Medicine Price Performance

NASDAQ IRON opened at $55.79 on Thursday. The firm’s fifty day moving average price is $62.73 and its 200 day moving average price is $53.69. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -13.99 and a beta of 0.75.

Institutional Investors Weigh In On Disc Medicine

Hedge funds have recently modified their holdings of the company. Amalgamated Bank lifted its stake in shares of Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after buying an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares during the last quarter. Quest Partners LLC purchased a new position in shares of Disc Medicine during the 3rd quarter worth $131,000. Quantbot Technologies LP acquired a new stake in shares of Disc Medicine during the third quarter worth $146,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Disc Medicine in the third quarter valued at $228,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Disc Medicine

In related news, CEO John D. Quisel sold 12,791 shares of Disc Medicine stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $66.01, for a total transaction of $844,333.91. Following the completion of the transaction, the chief executive officer now directly owns 72,065 shares in the company, valued at $4,757,010.65. The trade was a 15.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William Jacob Savage sold 9,158 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $59.64, for a total value of $546,183.12. Following the completion of the sale, the insider now owns 40,405 shares in the company, valued at $2,409,754.20. This represents a 18.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 85,758 shares of company stock valued at $5,400,990 in the last ninety days. Corporate insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.